Department of Laboratory medicine and Pediatrics, University of Saskatchewan, SHA, Saskatoon, Saskatchewan, Canada.
Division of Hematology Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
Pediatr Blood Cancer. 2022 Sep;69(9):e29793. doi: 10.1002/pbc.29793. Epub 2022 Jun 11.
Coagulopathy and thrombosis associated with SARS-CoV-2 infection are well defined in hospitalized adults and leads to adverse outcomes. Pediatric studies are limited.
An international multicentered (n = 15) retrospective registry collected information on the clinical manifestations of SARS-CoV-2 and multisystem inflammatory syndrome (MIS-C) in hospitalized children from February 1, 2020 through May 31, 2021. This sub-study focused on coagulopathy. Study variables included patient demographics, comorbidities, clinical presentation, hospital course, laboratory parameters, management, and outcomes.
Nine hundred eighty-five children were enrolled, of which 915 (93%) had clinical information available; 385 (42%) had symptomatic SARS-CoV-2 infection, 288 had MIS-C (31.4%), and 242 (26.4%) had SARS-CoV-2 identified incidentally. Ten children (1%) experienced thrombosis, 16 (1.7%) experienced hemorrhage, and two (0.2%) experienced both thrombosis and hemorrhage. Significantly prevalent prothrombotic comorbidities included congenital heart disease (p-value .007), respiratory support (p-value .006), central venous catheter (CVC) (p = .04) in children with primary SARS-CoV-2 and in those with MIS-C included respiratory support (p-value .03), obesity (p-value .002), and cytokine storm (p = .012). Comorbidities prevalent in children with hemorrhage included age >10 years (p = .04), CVC (p = .03) in children with primary SARS-CoV-2 infection and in those with MIS-C encompassed thrombocytopenia (p = .001) and cytokine storm (p = .02). Eleven patients died (1.2%), with no deaths attributed to thrombosis or hemorrhage.
Thrombosis and hemorrhage are uncommon events in children with SARS-CoV-2; largely experienced by those with pre-existing comorbidities. Understanding the complete spectrum of coagulopathy in children with SARS-CoV-2 infection requires ongoing research.
与 SARS-CoV-2 感染相关的凝血功能障碍和血栓形成在住院成人中已得到明确界定,并导致不良结局。儿科研究有限。
一项国际性多中心(n=15)回顾性登记研究收集了 2020 年 2 月 1 日至 2021 年 5 月 31 日期间住院儿童 SARS-CoV-2 和多系统炎症综合征(MIS-C)临床表现的信息。本研究亚组重点关注凝血功能障碍。研究变量包括患者人口统计学、合并症、临床表现、住院过程、实验室参数、管理和结局。
共纳入 985 例儿童,其中 915 例(93%)有临床信息可用;385 例(42%)有症状性 SARS-CoV-2 感染,288 例为 MIS-C(31.4%),242 例(26.4%)为 SARS-CoV-2 偶然检出。10 例(1%)儿童发生血栓形成,16 例(1.7%)发生出血,2 例(0.2%)发生血栓形成和出血。显著常见的促血栓形成合并症包括先天性心脏病(p 值.007)、呼吸支持(p 值.006)、中心静脉导管(CVC)(p 值.04)在原发性 SARS-CoV-2 患儿和 MIS-C 患儿中包括呼吸支持(p 值.03)、肥胖(p 值.002)和细胞因子风暴(p 值.012)。出血患儿中常见的合并症包括年龄>10 岁(p 值.04)、CVC(p 值.03)在原发性 SARS-CoV-2 感染患儿和 MIS-C 患儿中均包括血小板减少症(p 值.001)和细胞因子风暴(p 值.02)。11 例患者死亡(1.2%),无死亡归因于血栓形成或出血。
在 SARS-CoV-2 感染的儿童中,血栓形成和出血是罕见事件;主要发生在有既往合并症的患儿中。了解 SARS-CoV-2 感染儿童凝血功能障碍的全貌需要开展进一步的研究。